Skip to Content


In the US, Marqibo (vincristine liposome systemic) is a member of the drug class mitotic inhibitors and is used to treat Acute Lymphoblastic Leukemia.

US matches:

Ingredient matches for Marqibo


Vincristine sulfate (a derivative of Vincristine) is reported as an ingredient of Marqibo in the following countries:

  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.